Got my MYRX proxy today. You can vote online if you prefer by using the control number on your proxy. Hope to get the JAV proxy by tomorrow. As I stated before, I did not expect another bid for JAV and now it is too late as the vote will be completed very soon. Once merger is approved by shareholders, it will be too late for an offer. However, it would not surprise me for someone to make a bid for the combined company once merger is complete.
As an investor, I can't afford to wait for certainty. Azixa looked good in phase 2, and the pharmacodynamics make it a possible blockbuster. The number of patients who might try it as a last chance makes it a possible mega-blockbuster (VERY low probability). I have some of the stock, but I'm not screaming that it should be higher today.
It is interesting that in phase 2, too-rapid tumor necrosis, leading to bleeding, was a repeated adverse event. Improved dosing in phase 3 may overcome that.
"There's many a slip..." and all, but Azixa appears to have at least an even chance of making it in phase 3. That's pretty good.
"However, it would not surprise me for someone to make a bid for the combined company once merger is complete."
I'd be interested to see why you think someone else might do this. MYRX has lot's of cash, but no products even close to the market, and JAV has a product on the market that is not a big money maker. Just curious why you think someone would be more interested in them post-merger. I would think the opposite would have been more likely since the MYRX offer was the best one that JAV got, and since big pharma these days only wants things that have already made it through phase III.
You almost answered the question yourself. JAV has once product through Phase III and two in late Phase III. While MYRX has no late stage products, its pipeline includes some potential best in class drugs that would be huge. Big pharma was interested in JAV but management blew it. MYRX is too cheap and with JAV combined I feel will be very attractive to someone and incredibly cheap.